The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.

Competing Interests: AB reports unrelated research grants from Boehringer Ingelheim and Astra Zeneca, consulting fees paid to her institution from Boehringer Ingelheim, speaker fees paid to her institution from Hologic and General Electrics Healthcare, and is an advisory board member for Inventiva. PB reports speaker fees from Chiesi Farmaceutici and is a member of advisory boards for Sandoz, Biotest, and Kedrion. MB reports unrelated research grants from Gilead, consulting fees from Gilead, GSK, AbbVie, and Altimmune and speaker fees from Gilead, AbbVie, and Altimmune. PC reports unrelated research grants from Intercept and ANRS/MIE and INCA. PG reports unrelated grants from Gilead and Grifols, consulting fees from Gilead, RallyBio, SeaBeLife, MSD, Ocelot Bio, and Behring, and lecture fees from Pfizer. SH reports research grants from the National Institute for Health and Care Research, UK, and Public Health Scotland, NHS Scotland, and meeting support from EASL. THK reports consulting fees from MSD, Falk Pharma, and Albireo, speaker fees from Gilead, and he has owned stocks in Ultimovacs (unrelated to this topic). AK reports unrelated research grants from Novo Nordisk Foundation, Astra Zeneca, EU Horizon 2020, Innovationfund Denmark, Danish National Research Foundation, and Region of Southern Denmark, consulting fees from Resalis Therapeutics, AlphaSights, Takeda, and Zealand Pharma, royalties from Gyldendal, patents from Region of Southern Denmark and University of Southern Denmark, speaker fees from Norgine, Siemens, Novo Nordisk, and Nordic Bioscience, is an advisory board member for Norgine, Novo Nordisk, Boehringer Ingelheim, and Siemens, is a board member and co-founder of Evido (a small university spinout company developing data models for detection of chronic liver disease in primary care; he has no revenue in the company and receives no payment), and declares receipt of drugs, equipment, or services from Norgine, Siemens, Echosense, and Nordic Bioscience. MPM reports consulting fees from Assembly Bio, Bristol Myers Squibb, Falk Pharma, Gilead, GSK, Inventiva, MSD, Novartis, Otsuka/Visterra, Precision Biosciences, and Preglem/Gedeon Richter, speaker fees from AbbVie, Bristol Myers Squibb, Falk Pharma, Gilead, and MSD, unrelated travel support from AbbVie, Bristol Myers Squibb, Falk Pharma, Gilead, Merck (MSD), and Novartis, and is an advisory board member for Falk Pharma, Gilead, MSD, and Novartis. GS reports lecture fees from Otsuka Lundbeck. SZ-S reports consulting fees from Siemens and unrelated travel support from AbbVie. SK is the Deputy Editor of The Lancet. All other authors declare no competing interests. AK is Secretary General, MB is Public Health Councillor, and SZ-S is Public Health Councillor elect of EASL. The Commissioners are Harry Rutter, Patrizia Carrieri, Shira Zelber-Sagi, Eivind Engebretsen, Sharon Hutchinson, Kristin Voigt, Neil Guha, Annalisa Berzigotti, Georg Schomerus, Pere Gines, Maria Buti, Patrizia Burra, Michael P Manns, Aleksander Krag, Phil Newsome, Vlad Ratziu, Philippe Mathurin, Nuria Fabrellas, Michele Cecchini, Erika Duffell, Volkan Yomuk, Thomas Berg, Achim Kautz, Marcelo Naveira, Liana Gheorghe, and Tom H Karlsen. A Steering Committee governs the work of the Commission, formed by Aleksander Krag, Sabine Kleinert, Patrizia Burra, Michael P Manns, Maria Buti, and Shira-Zelber Sagi, and chaired by Tom H Karlsen.